Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPL | P06858 | 12/20 | 0.42 |
| ▸ | LIPG | Q9Y5X9 | 12/20 | 0.42 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 3/20 | 0.40 |
| ▸ | CA2 | P00918 | 3/20 | 0.40 |
| ▸ | CA9 | Q16790 | 3/20 | 0.40 |
| ▸ | CA12 | O43570 | 1/20 | 0.40 |
| ▸ | CA3 | P07451 | 1/20 | 0.40 |
| ▸ | CA4 | P22748 | 1/20 | 0.40 |
| ▸ | CA6 | P23280 | 1/20 | 0.40 |
| ▸ | CA5A | P35218 | 1/20 | 0.40 |
| ▸ | CA7 | P43166 | 1/20 | 0.40 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.40 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.40 |
| ▸ | F11 | P03951 | 2/20 | 0.36 |
| ▸ | P4HB | P07237 | 1/20 | 0.35 |
| ▸ | F2 | P00734 | 1/20 | 0.35 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.35 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.35 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14804365 | 0.85 | LPL (0.52) | LPLLIPGHIF1ACA1CA2 | |
| SCHEMBL16112310 | 0.85 | LPL (0.52) | LPLLIPGHIF1ACA1CA2 | |
| SCHEMBL3708268 | 0.82 | LPL (0.49) | LPLLIPGHIF1ACA1CA2 | |
| SCHEMBL3136657 | 0.82 | HIF1A (0.49) | LPLLIPGHIF1ACA1CA2 | |
| SCHEMBL5818521 | 0.81 | HIF1A (0.51) | LPLLIPGHIF1ACA1CA2 | |
| SCHEMBL15168492 | 0.80 | ESR2 (0.49) | LPLLIPGHIF1ACA1CA2 | |
| SCHEMBL578423 | 0.80 | QDPR (0.44) | LPLLIPGHIF1ACA1CA2 | |
| SCHEMBL2018524 | 0.80 | LPL (0.46) | LPLLIPGHIF1ACA1CA2 | |
| SCHEMBL20428742 | 0.80 | ESR2 (0.49) | LPLLIPGHIF1ACA1CA2 | |
| SCHEMBL17669557 | 0.79 | SOS1 (0.32) | HIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4352059-A1 | TRICYCLIC HETEROCYCLES AS FGFR INHIBITORS | Incyte Corporation (US) | 2024-04-17 | — | — | EP | disclosed |
| US-20230002385-A1 | TRICYCLIC HETEROCYCLES AS FGFR INHIBITORS | INCYTE CORPORATION | 2023-01-05 | — | — | US | disclosed |
| WO-2022261160-A1 | TRICYCLIC HETEROCYCLES AS FGFR INHIBITORS | INCYTE CORPORATION (US) | 2022-12-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230002385-A1 | TRICYCLIC HETEROCYCLES AS FGFR INHIBITORS | FGFR3, FGFR1, FGFR2 | LPL 2440/4885LIPG 1891/4885HIF1A 3205/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.